RCM
NBIX icon

RA Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

RA Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-24,400
Closed -$1.17M – 57
2015
Q2 		$1.17M Buy
+24,400
New +$1.03M 0.12% 47
2014
Q3 		– Sell
-68,968
Closed -$1.02M – 50
2014
Q2 		$1.02M Sell
68,968
-1,100,116
-94% -$15.5M 0.1% 27
2014
Q1 		$18.8M Buy
+1,169,084
New +$20M 1.35% 21

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's NBIX Position: Q3 2015 in Review

RA Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 24,400 shares — an estimated $1.17M sold.

RA Capital Management first reported a position in NBIX in Q1 2014 and held it in 3 quarters. The position peaked at $18.8M in Q1 2014. 208 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

  • RA Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
  • RA Capital Management sold 24,400 Neurocrine Biosciences shares in Q3 2015, an estimated $1.17M.
  • RA Capital Management first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 3 quarters.
  • RA Capital Management's Neurocrine Biosciences position peaked at $18.8M in Q1 2014.
  • 208 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.